Related Experiment Videos
["Adult T-cell leukemia"--a comment on the definition from the clinical view point (author's transl)]
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|November 1, 1980
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Immune system phenotyping of radiation and radiation combined injury in outbred mice.
Radiation research·2012
A simple and rapid enzymatic assay for the branched-chain alpha-ketoacid dehydrogenase complex using high-performance liquid chromatography.
Journal of inherited metabolic disease·2005
Differential diagnosis of neonatal mild hypergalactosaemia detected by mass screening: clinical significance of portal vein imaging.
Journal of inherited metabolic disease·2004
The Ca(2+)-ATPase of the scallop sarcoplasmic reticulum is of a cold-adapted type.
The Journal of membrane biology·2004
[Treatment landscape of mature NK/T-cell lymphomas: treatment outcomes in Japan and future prospects].
[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
[Prophylactic or pre-emptive therapy with azacitidine or FLT3 inhibitor after allogeneic hematopoietic stem cell transplantation for AML and MDS].
[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
[Prophylactic use of tyrosine kinase inhibitors after allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia].
[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
[Development of universal off-the-shelf T cell therapies derived from ES/iPS cells for leukemia and COVID-19].
[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
[Predictors of treatment-free remission (TFR) and second TFR attempts in chronic myeloid leukemia].
[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
[Complement-coagulation crosstalk in immunothrombosis].
[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Donanemab for early symptomatic AD in the UK-indicated population: safety and efficacy in those who are non-carriers or heterozygous for APOE ε4.
Neurodegenerative disease management·2026